source
- PepGen reports promising early results for myotonic dystrophy type 1 drug in six-patient trialPepGen announced that its experimental therapy for myotonic dystrophy type 1 showed the most encouraging early data yet in a small study. The trial involved six patients who received the drug for 1…
- FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence riskThe Food and Drug Administration has approved Bayer's new medication intended to prevent another stroke in patients who have already experienced one. The drug, sold under the brand name Sunharbo,…